المؤلفون: T. V. Dubinina, A. M. Lila, E. V. Kvasova, E. M. Agafonova, I. A. Andrianova, L. V. Ivanova, D. V. Yurk, N. A. Garaeva, E. Y. Akulinushkina, A. N. Vedekhina, I. B. Bashkova, S. A. Lapshina, Y. Y. Grabovetskaya, N. F. Semenova, M. I. Valkova, D. G. Krechikova, O. S. Mazhaeva, I. B. Vinogradova, O. V. Bugrova, S. M. Voloshenko, G. R. Enikeeva, E. S. Immis, L. F. Timasheva, E. E. Biserova, L. Z. Shaimukhametova, I. M. Patrikeeva, A. A. Barakat, P. A. Shesternya, N. M. Nikitina, M. I. Yupatova, O. N. Anoshenkova, M. A. Korolev, Y. B. Ubshaeva, E. A. Vasilenko, E. V. Zonova, O. B. Nesmeyanova, E. A. Bogdanova, V. I. Mazurov, R. R. Samigullina, I. M. Marusenko, Т. В. Дубинина, А. М. Лила, Е. В. Квасова, Е. М. Агафонова, И. А. Андрианова, Л. В. Иванова, Д. В. Юрк, Н. А. Гараева, Е. Ю. Акулинушкина, А. Н. Ведёхина, И. Б. Башкова, С. А. Лапшина, Ю. Ю. Грабовецкая, Н. Ф. Семенова, М. И. Валькова, Д. Г. Кречикова, О. С. Мажаева, И. Б. Виноградова, О. В. Бугрова, М. С. Волошенко, Г. Р. Еникеева, Е. С. Иммис, Л. Ф. Тимашева, Е. Э. Бисерова, Л. З. Шаймухаметова, И. М. Патрикеева, А. А. Баракат, П. А. Шестерня, Н. М. Никитина, М. И. Юпатова, О. Н. Аношенкова, М. А. Королев, Ю. Б. Убшаева, Е. А. Василенко, Е. В. Зонова, О. Б. Несмеянова, Е. А. Богданова, В. И. Мазуров, Р. Р. Самигулина, И. М. Марусенко

المصدر: Modern Rheumatology Journal; Том 18, № 2 (2024); 41-50 ; Современная ревматология; Том 18, № 2 (2024); 41-50 ; 2310-158X ; 1996-7012

مصطلحات موضوعية: лечение, non-radiological axial spondyloarthritis, diagnosis, treatment, нерентгенологический аксиальный спондилоартрит, диагностика

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/1560/1456; Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60.; Rudwaleit M, van der Heijde D, Landewe R,et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009 Jun;68(6):777-83. doi:10.1136/ard.2009.108233. Epub 2009 Mar 17.; Baraliakos X, Hermann KG, Braun J. Imaging in axial spondyloarthritis: diagnostic problems and pitfalls. Rheum Dis Clin North Am. 2012 Aug;38(3):513-22. doi:10.1016/j.rdc.2012.08.011. Epub 2012 Sep 25.; Kleinert S, Schuch F, Rapp P, et al. Radiographic and non-radiographic axial spondyloarthritis are not routinely distinguished in everyday clinical care: an analysis of real-world data from rheumatology practices. Rheumatol Int. 2024 Apr;44(4):653-661. doi:10.1007/s00296-023-05463-7. Epub 2023 Oct 8.; Akkoc N, Khan MA. Is Axial Spondyloarthritis More Common Than Rheumatoid Arthritis? Curr Rheumatol Rep. 2020 Jul 25;22(9): 54. doi:10.1007/s11926-020-00934-3; Hocevar A, Potocnik Pucelj N, Jese R, et al. The incidence of spondyloarthritis in Slovenia. Medicine (Baltimore). 2019 Jun; 98(26):e16177. doi:10.1097/MD.0000000000016177; Лила АМ, Древаль РО, Шипицын ВВ. Оценка организации медицинской помощи и лекарственного обеспечения при ревматических заболеваниях и социальноэкономического бремени этих болезней в Российской Федерации. Современная ревматология. 2018;12(3):112-119. doi:10.14412/1996-7012-2018-3-112-11.; McGonagle D, Ramonda R, Scagnellato L, Scriffignano S, Weddell J, Lubrano E. A strategy towards disentangling treatment refractory from misdiagnosed axial Spondyloarthritis. Autoimmun Rev. 2023 Aug 3:103405. doi:10.1016/j.autrev.2023.103405. Epub ahead of print.; Hermann J, Giessauf H, Schaffler G, et al.Early spondyloarthritis: usefulness of clinical screening. Rheumatology (Oxford). 2009 Jul; 48(7):812-6. doi:10.1093/rheumatology/ kep119; Mauro D, Forte G, Poddubnyy D, Ciccia F.The Role of Early Treatment in the Management of Axial Spondyloarthritis: Challenges and Opportunities. Rheumatol Ther. 2024 Feb; 11(1):19-34. doi:10.1007/s40744-023-00627-0. Epub 2023 Dec 18.; Смирнов АВ, Эрдес ШФ. Оптимизация рентгенодиагностики анкилозирующего спондилита в клинической практике – значимость обзорного снимка таза. Научно-практическая ревматология. 2015; 53(2):175-181.; Тюхова ЕЮ. Магнитно-резонанснаятомография позвоночника и крестцовоподвздошных суставов у больных спондилоартритами. Научно-практическая ревматология. 2012;50(2):106-111.; Feldtkeller E, Bruckel J, Khan MA. Scientific contributions of ankylosing spondylitis patient advocacy groups. Curr Opin Rheumatol. 2000 Jul;12(4):239-47. doi:10.1097/00002281-200007000-00002; Дубинина ТВ, Эрдес ШФ. Причины поздней диагностики анкилозирующего спондилита в клинической практике. Научно-практическая ревматология. 2010; 48(2):43-48.; Redeker I, Callhoff J, Hoffmann F, et al. Determinants of diagnostic delay in axial spondyloarthritis: an analysis based on linked claims and patient-reported survey data. Rheumatology (Oxford). 2019 Sep 1;58(9): 1634-1638. doi:10.1093/rheumatology/kez090; Navarro-Compan V, Benavent D, Capelusnik D, et al. ASAS consensus definition of early axial spondyloarthritis. Ann Rheum Dis. 2023 Jun 15:ard-2023-224232. doi:10.1136/ard-2023-224232. Online ahead of print.; Лапшина СА, Мясоутова ЛИ, Мухина РГ, Салихов ИГ. Результативность образовательных программ по раннему выявлению анкилозирующего спондилита для врачей первичного звена в г. Казани. Научно-практическая ревматология. 2014; 52(2):183-186.; Magrey M, Schwartzman S, de Peyrecave N, et al. Nonradiographic axial spondyloarthritis: expanding the spectrum of an old disease: A narrative review. Medicine (Baltimore). 2022 Apr 15;101(15):e29063. doi:10.1097/MD.0000000000029063; Robinson PC, van der Linden S, Khan MA,Taylor WJ. Axial spondyloarthritis: concept, construct, classification and implications for therapy. Nat Rev Rheumatol. 2021 Feb;17(2): 109-118. doi:10.1038/s41584-020-00552-4. Epub 2020 Dec 23.; Ez-Zaitouni Z, Bakker PAC, van Lunteren M, et al. Presence of multiple spondyloarthritis (SpA) features is important but not sufficient for a diagnosis of axial spondyloarthritis: data from the SPondyloArthritis Caught Early (SPACE) cohort. Ann Rheum Dis. 2017 Jun;76(6):1086-1092. doi:10.1136/annrheumdis-2016-210119. Epub 2017 Jan 6.; Румянцева ДГ, Эрдес ШФ. Аксиальныйспондилоартрит: современный взгляд на концепцию и эволюцию болезни. Современная ревматология. 2019;13(4):4-10.; Румянцева ДГ, Дубинина ТВ, Демина АБи др. Анкилозирующий спондилит и нерентгенологический аксиальный спондилоартрит: две стадии одной болезни? Терапевтический архив. 2017;89(5):33-7.; Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2023 Jan;82(1): 19-34. doi:10.1136/ard-2022-223296. Epub 2022 Oct 21.; https://mrj.ima-press.net/mrj/article/view/1560

الاتاحة: https://mrj.ima-press.net/mrj/article/view/1560
https://doi.org/10.14412/19967012-2024-2-41-50

المؤلفون: A. A. Baranov, I. B. Vinogradova, O. N. Anoshenkova, O. V. Antipova, E. A. Bogdanova, Y. Y. Grabovetskaya, E. P. Ilivanova, A. N. Kalyagin, I. N. Kushnir, N. A. Lapkina, M. V. Mokrousova, O. B. Nesmeyanova, N. M. Nikitina, P. A. Shesternya, N. V. Yudina, E. Feist, E. L. Nasonov, А. А. Баранов, И. Б. Виноградова, О. Н. Аношенкова, О. В. Антипова, Е. А. Богданова, Ю. Ю. Грабовецкая, Е. П. Иливанова, А. Н. Калягин, И. Н. Кушнир, Н. А. Лапкина, М. В. Мокроусова, О. Б. Несмеянова, Н. М. Никитина, П. А. Шестерня, Н. В. Юдина, Е. Л. Насонов

المصدر: Rheumatology Science and Practice; Vol 61, No 3 (2023); 307-319 ; Научно-практическая ревматология; Vol 61, No 3 (2023); 307-319 ; 1995-4492 ; 1995-4484

مصطلحات موضوعية: исходы, IL-6 inhibitor, olokizumab, disease activity, outcomes, ингибиторы ИЛ-6, олокизумаб, активность заболевания

وصف الملف: application/pdf

Relation: https://rsp.mediar-press.net/rsp/article/view/3358/2286; Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi:10.1016/S0140-6736(16)30173-8; Favalli EG. Understanding the role of interleukin-6 (IL-6) in the joint and beyond: A comprehensive review of IL-6 inhibition for the management of rheumatoid arthritis. Rheumatol Ther. 2020;7(3):473-516. doi:10.1007/s40744-020-00219-2; Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина-6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599. doi:10.14412/1995-4484-2017-590-599; Насонов ЕЛ. Новые возможности фармакотерапии иммуновоспалительных ревматических заболеваний: фокус на ингибиторы интерлейкина 17. Научно-практическая ревматология. 2017;55(1):68-86. doi:10.14412/1995-4484-2017-68-86; Насонов ЕЛ, Каратеев ДЕ. Ревматоидный артрит. В: Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2020:17-57.; Fraenkel L, Bathon JM, England BR, StClair EW, Arayssi T, Carandang K, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73(7):1108-1123. doi:10.1002/art.41752; Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, D ougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655; Насонов ЕЛ. Метотрексат при ревматоидном артрите – 2015: новые факты и идеи. Научно-практическая ревматология. 2015;53(4):64-76. doi:10.14412/1995-4484-2015-64-76; Kondo M, Yamada H. Drug survival rates of biological diseasemodifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: A 14-year retrospective study from a rheumatology clinic in Japan. Mod Rheumatol. 2019;29(6): 928-935. doi:10.1080/14397595.2018.1537556; Samartín-Ucha M, Pego-Reigosa JM, Álvarez-Payero M, Martin-Vila A, Pineiro-Corrales G, Rodriguez-Rodriguez M, et al. Medication persistence on biological therapies prescribed for the treatment of chronic inflammatory arthropathies: A real-world data study. Eur J Hosp Pharm. 2021;28(Suppl 2):e47-e50. doi:10.1136/ejhpharm-2019-002133; Насонов ЕЛ. Фармакотерапия ревматоидного артрита: новая стратегия, новые мишени. Научно-практическая ревматология. 2017;55(4):409-419. doi:10.14412/1995-4484-2017-409-419; Aletaha D, Kerschbaumer A, Kastrati K, Dejaco C, Dougados M, McInnes IB, Sattar N, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: An update. Ann Rheum Dis. 2023;82(6):773-787. doi:10.1136/ard-2022-222784; Насонов ЕЛ, Файст Е. Перспективы ингибиции интерлейкина-6 при ревматоидном артрите: олокизумаб (новые моноклональные антитела к ИЛ-6). Научно-практическая ревматология. 2022;60(5):505-518. doi:10.47360/1995-4484-2022-505-518; Nasonov E, Fatenejad S, Feist E, Ivanova M, Korneva E, Krechikova DG, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(4):469-479. doi:10.1136/annrheumdis-2021-219876; Feist E, Fatenejad S, Grishin S, Korneva E, Luggen ME, Nasonov E, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: Efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022;81(12):1661-1668. doi:10.1136/ard-2022-222630; Shaw S, Bourne T, Meier C, Carrington B, Gelinas R, Henry A, et al. Discovery and characterization of olokizumab: A humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014;6(3):774-782. doi:10.4161/mabs.28612; Kretsos K, Golor G, Jullion A, Hickling M, McCabe S, Shaw S, et al. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. Clin Pharmacol Drug Dev. 2014;3(5):388-395. doi:10.1002/cpdd.121; Smolen JS, Feist E, Fatenejad S, Grishin SA, Korneva EV, Nasonov EL, et al.; CREDO2 Group. Olokizumab versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2022;387(8): 715-726. doi:10.1056/NEJMoa2201302; Mahmoud AM. Olokizumab’s effectiveness and safety in patients with rheumatoid arthritis: A systematic review and meta-analysis of randomized controlled trials. J Clin Densitom. 2023;26(1):61-82. doi:10.1016/j.jocd.2022.12.003; Ho Lee Y, Gyu Song G. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials. Z Rheumatol. 2023 Jan 6. doi:10.1007/s00393-022-01315-0; Smolen JS, Landewé RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356; Emery P, van Hoogstraten H, Thangavelu K, Mangan E, St John G, Verschueren P. Subcutaneous sarilumab in patients with rheumatoid arthritis who previously received subcutaneous sarilumab or intravenous tocilizumab: An open-label extension of a randomized clinical trial. ACR Open Rheumatol. 2020;2(11): 672-680. doi:10.1002/acr2.11188; Tony HP, Feist E, Aries PM, Zinke S, Krüger K, Ahlers J, et al. Sarilumab reduces disease activity in rheumatoid arthritis patients with inadequate response to janus kinase inhibitors or tocilizumab in regular care in Germany. Rheumatol Adv Pract. 2022;6(1):rkac002. doi:10.1093/rap/rkac002; Taylor PC, Cerinic MM, Alten R, Avouac J, Westhovens R. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: Optimising treatment outcomes Adv Musculoskelet Dis. 2022;14:1-14. doi:10.1177/1759720X221114101; Bhushan V, Lester S, Briggs L, Hijjawi R, Shanahan EM, Pontifex E, et al. Real-life retention rates and reasons for switching of biological DMARDs in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Front Med (Lausanne). 2021;8:708168. doi:10.3389/fmed.2021.708168; Den Broeder N, Den Broeder A, Verhoef LM, Van den Hoogen F, Van der Maas A, Van den Bemt B. Non-medical switching from tocilizumab to sarilumab in rheumatoid artritis patients with low disease activity. Ann Rheum Dis. 2022;81(Suppl 1):593-594. doi:10.1136/annrheumdis-2022-eular.2156; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Smolen JS, Kay J, Matteson EL, Landewé R, Hsia EC, Xu S, et al. Insights into the efficacy of golimumab plus methotrexate in patients with active rheumatoid arthritis who discontinued prior anti-tumour necrosis factor therapy: Post-hoc analyses from the GO-AFTER study. Ann Rheum Dis. 2014;73(10):1811-1818. doi:10.1136/annrheumdis-2013-203435; Авдеева АС, Мисиюк АС, Сатыбалдыев АМ, Лукина ГВ, Сороцкая ВН, Жиляев ЕВ, и др. Анализ результатов терапии тофацитинибом в реальной клинической практике (по данным Общероссийского регистра больных артритом ОРЕЛ). Научно-практическая ревматология. 2020;58(3):262-267. doi:10.14412/1995-4484-2020-262-267; Huizinga TW, Conaghan PG, Martin-Mola E, Schett G, Amital H, Xavier RM, et al. Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study. Ann Rheum Dis. 2015;74(1):35-43. doi:10.1136/annrheumdis-2014-205752; Kastrati K, Aletaha D, Burmester GR, Chwala E, Dejaco C, Dougados M, et al. A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases. RMD Open. 2022;8(2):e002359. doi:10.1136/rmdopen-2022-002359; https://rsp.mediar-press.net/rsp/article/view/3358

الاتاحة: https://rsp.mediar-press.net/rsp/article/view/3358
https://doi.org/10.47360/1995-4484-2023-307-319

المؤلفون: A. V. Pak, E. A. Pashkov, N. D. Abramova, A. V. Poddubikov, F. G. Nagieva, E. A. Bogdanova, E. P. Pashkov, O. A. Svitich, V. V. Zverev, А. В. Пак, Е. А. Пашков, Н. Д. Абрамова, А. В. Поддубиков, Ф. Г. Нагиева, Е. А. Богданова, Е. П. Пашков, О. А. Свитич, В. В. Зверев

المساهمون: The study was carried out using the scientific equipment of the Center for Collective Use of the I. Mechnikov Research Institute of Vaccines and Sera, and supported by the Ministry of Science and Higher Education of the Russian Federation, Agreement No. 075-15-2021-676 dated July 28, 2021., Исследование выполнено с использованием научного оборудования Центра коллективного пользования Научно-исследовательского института вакцин и сывороток им. И.И. Мечникова Министерства здравоохранения Российской Федерации при финансовой поддержке Министерства науки и высшего образования Российской Федерации, соглашение № 075-15-2021-676 от 28.07.2021.

المصدر: Fine Chemical Technologies; Vol 17, No 5 (2022); 384-393 ; Тонкие химические технологии; Vol 17, No 5 (2022); 384-393 ; 2686-7575 ; 2410-6593

مصطلحات موضوعية: вирусная РНК, IL-1β, influenza A virus, IFN-λ3, gene expression, siRNA, pro-inflammatory cytokines, IL-28β, viral RNA, вирус гриппа А, экспрессия генов, миРНК, провоспалительные цитокины

وصف الملف: application/pdf

Relation: https://www.finechem-mirea.ru/jour/article/view/1880/1875; https://www.finechem-mirea.ru/jour/article/view/1880/1876; https://www.finechem-mirea.ru/jour/article/downloadSuppFile/1880/728; Пашков Е.А., Коротышева М.О., Пак А.В., Файзулоев Е.Б., Сидоров А.В., Поддубиков А.В., Быстрицкая Е.П., Дронина Ю.Е., Солнцева В.К., Зайцева Т.А., Пашков Е.П., Быков А.С., Свитич О.А., Зверев В.В. Исследование противогриппозной активности комплексов миРНК против клеточных генов FLT4, Nup98 и Nup205 на модели in vitro. Тонкие химические технологии. 2022;17(2):140–151. https://doi.org/10.32362/2410-6593-2022-17-2-140-151; Пашков Е.А., Файзулоев Е.Б., Корчевая Е.Р., Ртищев А.А., Черепович Б.С., Сидоров А.В., Поддубиков А.В., Быстрицкая Е.П., Дронина Ю.Е., Быков А.С., Свитич О.А., Зверев В.В. Нокдаун клеточных генов FLT4, Nup98 и Nup205 как супрессор вирусной активности гриппа А/WSN/33 (H1N1) в культуре клеток А549. Тонкие химические технологии. 2021;16(6):476–489. https://doi.org/10.32362/2410-6593-2021-16-6-476-489; Sellers S.A., Hagan R.S., Hayden F.G., Fischer W.A. II. The hidden burden of influenza: A review of the extrapulmonary complications of influenza infection. Influenza Other Respir. Viruses. 2017;11(5):372–393. https://doi.org/10.1111/irv.12470; Koehler P., Βassetti M., Kochanek M., Shimabukuro-Vornhagen A., Cornely O.A. Intensive care management of influenza-associated pulmonary aspergillosis. Clin. Microbiol. Infect. 2019;25(12):1501–1509. https://doi.org/10.1016/j.cmi.2019.04.031; Radzišauskienė D., Vitkauskaitė M., Žvinytė K., Mameniškienė R. Neurological complications of pandemic A(H1N1)2009pdm, postpandemic A(H1N1)v, and seasonal influenza A. Βrain Βehav. 2021;11(1):e01916. https://doi.org/10.1002/brb3.1916; Kalil A.C., Thomas P.G. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit. Care. 2019;23(1):258. https://doi.org/10.1186/s13054-019-2539-x; Plotnikova M.A., Klotchenko S.A., Vasin A.V. Development of a multiplex quantitative PCR assay for the analysis of human cytokine gene expression in influenza A virus-infected cells. J. Immunol. Methods. 2016;430:51–55. https://doi.org/10.1016/j.jim.2016.01.005; Wang J., Wu Y., Ma C., Fiorin G., Wang J., Pinto L.H., et al. Structure and inhibition of the drug-resistant S31N mutant of the M2 ion channel of influenza A virus. Proc. Natl. Acad. Sci. USA. 2013;110(4):1315–1320. https://doi.org/10.1073/pnas.1216526110; Lampejo T. Influenza and antiviral resistance: an overview. Eur. J. Clin. Microβiol. Infect. Dis. 2020;39(7):1201–1208. https://doi.org/10.1007/s10096-020-03840-9; Leneva I.A., Russell R.J., Βoriskin Y.S., Hay A.J. Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol. Antiviral Res. 2009;81(2):132–140. https://doi.org/10.1016/j.antiviral.2008.10.009; Goldhill D.H., Te Velthuis A.J.W., Fletcher R.A., Langat P., Zambon M., Lackenby A., Βarclay W.S. The mechanism of resistance to favipiravir in influenza. Proc. Natl. Acad. Sci. USA. 2018;115(45):11613–11618. https://doi.org/10.1073/pnas.1811345115; Yang H., Winkler W., Wu X. Interferon Inducer IFI35 regulates RIG-I-mediated innate antiviral response through mutual antagonism with Influenza protein NS1. J. Virol. 2021;95(11):e00283–21. https://doi.org/10.1128/jvi.00283-21; Sa Ribero M., Jouvenet N., Dreux M., Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16(7):e1008737. https://doi.org/10.1371/journal.ppat.1008737; Hauser P., Khosla J., Aurora H., Laurin J., Kling M.A., Hill J., Gulati M., Thornton A.J., Schultz R.L., Valentine A.D., Meyers C.A., Howell C.D. A prospective study of the incidence and open-label treatment of interferoninduced major depressive disorder in patients with hepatitis C. Mol. Psychiatry. 2002;7(9):942–947. https://doi.org/10.1038/sj.mp.4001119; Han J., Perez J., Schafer A., Cheng H., Peet N., Rong L., et al. Influenza virus: small molecule therapeutics and mechanisms of antiviral resistance. Curr. Med. Chem. 2018;25(38):5115–5127. https://doi.org/10.2174/0929867324666170920165926; Fire A.Z. Gene silencing by double-stranded RNA. Cell Death Differ. 2007;14(12):1998–2012. https://doi.org/10.1038/sj.cdd.4402253; Fire A., Xu S.Q., Montgomery M.K., Kostas S.A., Driver S.E., Mell C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–811. https://doi.org/10.1038/35888; Estrin M.A., Hussein I.T.M., Puryear W.Β., Kuan A.C., Artim S.C., Runstadler J.A. Host-directed combinatorial RNAi improves inhibition of diverse strains of influenza A virus in human respiratory epithelial cells. PLoS One. 2018;13(5):e0197246. https://doi.org/10.1371/journal.pone.0197246; Пашков Е.А., Корчевая Е.Р., Файзулоев Е.Б., Пашков Е.П., Зайцева Т.А., Ртищев А. А., Поддубиков А.В., Свитич О.А., Зверев В.В. Создание модели изучения противовирусного действия малых интерферирующих РНК in vitro. Санитарный врач. 2022;1. https://doi.org/10.33920/med-08-2201-07; Park H.S., Liu G., Thulasi Raman S.N., Landreth S.L., Liu Q., Zhou Y. NS1 Protein of 2009 Pandemic Influenza A Virus Inhibits Porcine NLRP3 Inflammasome-Mediated Interleukin-1 Βeta Production by Suppressing ASC Uβiquitination. J. Virol. 201828;92(8):e00022–18. https://doi.org/10.1128/JVI.00022-18; Julkunen I., Melén K., Nyqvist M., Pirhonen J., Sareneva T., Matikainen S. Inflammatory responses in influenza A virus infection. Vaccine. 2000;19(Suppl. 1):S32–S37. https://doi.org/10.1016/S0264-410X(00)00275-9; Lee H.K, Loh T.P., Lee C.K., Tang J.W., Chiu L., Koay E.S. A universal influenza A and B duplex real-time RT-PCR assay. J. Med. Virol. 2012;84(10):1646–1651. https://doi.org/10.1002/jmv.23375; Piasecka J., Lenartowicz E., Soszynska-Jozwiak M., Szutkowska B., Kierzek R., Kierzek E. RNA Secondary Structure Motifs of the Influenza A Virus as Targets for siRNA-Mediated RNA Interference. Mol. Ther. Nucleic Acids. 2020;19:627–642. https://doi.org/10.1016/j.omtn.2019.12.018; https://www.finechem-mirea.ru/jour/article/view/1880

الاتاحة: https://www.finechem-mirea.ru/jour/article/view/1880
https://doi.org/10.32362/2410-6593-2022-17-5-384-393

المؤلفون: null Д. Ж. Алишева, null Ж. К. Алтайбаева, null Е. А. Богданова, null Г. К. Бейсембаева

المصدر: Bulletin of Toraighyrov University. Economics series. :6-16

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::7dcc769e6154c4730d59dd8a7769be54
https://doi.org/10.48081/fvwq3312

المؤلفون: O. B. Nesmeyanova, G. M. Khusainova, E. A. Bogdanova, O. V. Solovyeva, K. P. Ratushnaya, A. N. Kharkova, О. Б. Несмеянова, Г. М. Хусаинова, Е. А. Богданова, О. В. Соловьева, К. П. Ратушная, А. Н. Харькова

المصدر: Modern Rheumatology Journal; Том 13, № 4 (2019); 75-78 ; Современная ревматология; Том 13, № 4 (2019); 75-78 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2019-4

مصطلحات موضوعية: артериит Такаясу, Takayasu arteritis

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/961/922; Эрдес ШФ, Бадокин ВВ, Бочкова АГ и др. О терминологии спондилоартритов. Научно-практическая ревматология. 2015;53(6):657-60. doi:10.14412/1995-4484-2015-657-660; Yasemin O. Cardiac Involvement in Ankylosing Spondylitis. J Clin Med Res. 2016 Jun; 8(6):427-430. doi:10.14740/jocmr2488w; Matsushita M, Kobayashi S, Tada K, et al. A case of ankylosing spondylitis with concurrent Takayasu arteritis. J Int Med Res. 2018 Jun; 46(6):2486-2494. doi:10.1177/0300060518769548. Epub 2018 Apr 24.; Бекетова ТВ, Насонов ЕЛ. Современная классификация системных васкулитов. Терапевтический архив. 2014;(5):94-8.; Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum. 1990 Aug;33(8): 1129-34.; Насонов ЕЛ, редактор. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа; 2017. 464 с.; Grygotis L. Large-Vessel Vasculitis Classification: Draft Criteria Presented at ACR/ARHP 2018. https://www.rheumatol-ogyadvisor.com/home/conference-highlights/acr-2018-coverage/large-vessel-vasculitis-classification-draft-criteria-presented-at-acr-arhp-2018/; Покровский А, Зотиков А, Грязнов О. Неспецифический аортоартериит: Перспективы лечения. Врач. 2002;(5):3-6.; Ассоциация ревматологов России. Федеральные клинические рекомендации по диагностике и лечению системных васкулитов. Москва, 2013.; Terao C. History of Takayasu arteritis and Dr. Mikito Takayasu. Int J Rheum Dis. 2014 Nov; 17(8):931-5. doi:10.1111/1756-185X.12576.; Riviere E, Arnaud L, Ebbo M, et al. Takayasu Arteritis and Spondyloarthritis: Coincidence or Association? A Study of 14 Cases. J Rheumatol. 2017 Jul;44(7): 1011-1017. doi:10.3899/jrheum.160762.; Mielnik P, Hjelle AM, Nordeide JL. Coexistence of Takayasu’s arteritis and ankylosing spondylitis may not be accidental – Is there a need for a new subgroup in the spondyloarthritis family? Mod Rheumatol. 2018 Mar;28(2):313-318. doi:10.1080/14397595.2017.1341592.; Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population. Am J Hum Genet. 2013 Aug 8;93(2):289-97. doi:10.1016/j.ajhg.2013.05.024.; Галушко ЕА, Гордеев АВ. Современный взгляд на патогенез спондилоартритов – молекулярные механизмы. Научно-практическая ревматология. 2015;53(3): 299-307.; Terao C, Yoshifuji H, Nakajima T, et al. Ustekinumab as a therapeutic option for Takayasu arteritis: from genetic findings to clinical application. Scand J Rheumatol. 2016 Jan;45(1):80-82. doi:10.3109/03009742.2015.1060521. Epub 2015 Aug 31.; Souabni L, Ben Abdelghani K, Jradi S, et al. Takayasu's arteritis occurring under TNF-α blockers: a new paradoxical effect? BMJ Case Rep. 2014 Nov 24;2014. pii: bcr2014204226. doi:10.1136/bcr-2014-204226.; Насонов ЕЛ, Баранов АА, Шилкина НП. Васкулиты и васкулопатии. Ярославль: Верхняя Волга; 1999. 616 с.; Carvalho ES, de Souza AW, Leao SC, et al. Absence of mycobacterial DNA in peripheral blood and artery specimens in patients with Takayasu arteritis. Clin Rheumatol. 2017 Jan; 36(1): 205-208. doi:10.1007/s10067-016-3400-0; https://mrj.ima-press.net/mrj/article/view/961

الاتاحة: https://mrj.ima-press.net/mrj/article/view/961
https://doi.org/10.14412/1996-7012-2019-4-75-78

المؤلفون: null Ж. К. Алтайбаева, null Е. А. Богданова, null Г. К. Бейсембаева, null Е. Т. Шахман

المصدر: Bulletin of Toraighyrov University. Economics series. :18-28

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::d2f208478b4891b87cadb2b67df50782
https://doi.org/10.48081/uxzi2000

المؤلفون: L. V. Adamyan, E. A. Bogdanova, E. V. Sibirskaya, T. M. Glybina, M. B. Garunova, Л. В. Адамян, Е. А. Богданова, Е. В. Сибирская, Т. М. Глыбина, М. Б. Гарунова

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 59, № 2 (2014); 43-47 ; Российский вестник перинатологии и педиатрии; Том 59, № 2 (2014); 43-47 ; 2500-2228 ; 1027-4065 ; undefined

مصطلحات موضوعية: адренокортикотропный гормон, congenital adrenal hyperplasia, reproductive health, 11'-hydroxyprogesterone, adrenocorticotropic hormone, врожденная гиперплазия коры надпочечников, репродуктивное здоровье, 17-гидроксипрогестерон

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/203/243; BongiovanniA.M., RootA.W. The adrenogenital syndrome. N Engl J Med 1963; 268: 1283-1399.; Gallais A. Le syndrome genitosurrenal, etude anatomo-clinique. Paris 1912; 224.; Верещинский А. О. Надпочечно-половой синдром с точки зрения хирургической патологии и терапии. Вестн хир 1923; 4: 3: 207—219. (Vereshchynsky A.O. Adrenal-sexual syndrome in terms of surgical pathology and therapy. Vestn khir 1923; 4: 3: 207-219.); Therrell B. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 1:15—30.; Pang S., Murphey W., Levine L.S. et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 3: 413-420.; Pang S., Wallace M. Hofman L. et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 6: 866—874.; Speiser P., Dupont В., Rubinstein P. et al. High frequency of nonclassical steroid 21-hydroxylase deficiency. Am J Hum Genet 1985; 4: 650—667.; Fitness J., Dixit N., Webster D. et al. Genotyping of CYP21, linked chromosome 6p markers, and a sex-specific gene in neonatal screening for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1999; 3: 960—966.; Cam J., Moshang T. Jr., Bongiovanni A.M. et al. Elevated 17-hydroxyprogesterone and testosterone in a newborn with; beta-hydroxysteroid dehydrogenase deficiency. N Engl J Med 1985; 10: 618-621.; Speiser P., Dupont J., Zhu D. et al. Disease expression and molecular genotype in congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Invest 1992; 2: 584—595.; Wtchel S., Lee P. /dentification of heterozygotic carriers of 21-hydroxylase deficiency: sensitivity of ACTH stimulation tests. Am J Med Genet 1982; 4: 337—342.; Clayton P., Miller W., Oberfield S.E. et al. Consensus statement on 21-hydroxylase deficiency from the European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society. Horm Res 2002; 4: 188—195.; White P., Speiser P. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 3: 245—291.; Pang S., Spence D.A., New M.I. Newborn screening for congenital adrenal hyperplasia with special reference to screening in Alaska. AnnNYAcad Sci 1985; 458: 90—102.; Pang S.Y., Wallace M.A., Hofman L. et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81:6:866—874.; Карева М.А., Орлова Е.М. Адреногенитальный синдром: прошлое, настоящее и будущее. Пробл эндокринол 2011; 1: 66—70. (Kareva M.A., Orlova E.M. Adrenogenital syndrome: past, present and future. Probljendokrinol 2011; 1: 66-70.); Forest M., Morel Y, David M. et al. Prenatal treatment of congenital adrenal hyperplasia. Trends Endocrinol Metab 1998; 7: 284-289.; New M., Carlson A., Obeid J. et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001; 12: 5651-5657.; Morel Y, Miller L. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Adv Hum Genet 1991; 20: 1—68.; Partsch C, Sippell W, MacKenzie I.Z. et al. The steroid hormonal milieu of the undisturbed human fetus and mother at 16-20 weeks gestation. J Clin Endocrinol Metab 1991; 5: 969—974.; Kay H, Bird I., Coe C.L. et al. Antenatal steroid treatment and adverse fetal effects: what is the evidence? J Soc Gynecol Investig 2000; 5: 269-278.; AlizaiN., Thomas D., LilfordRJ. et al. Feminizing genitoplasty for congenital adrenal hyperplasia: what happens at puberty? JUrol 1999; 5: 1588-1591.; Elhalaby E., Abo Sikeena M. Delayed presentation of congenital diaphragmatic hernia. Pediatr Surg Int 2002; 5-6: 480-485.; Mullis P., Hindmarsh P., Brook C.G. et al. Sodium chloride supplement at diagnosis and during infancy in children with salt-losing 21-hydroxylase deficiency. Eur J Pediatr 1990; 1: 22—25.; Charmandari E., Lichtarowicz-Krynska E., Hindmarsh PC. etal. Congenital adrenal hyperplasia: management during critical illness. Arch Dis Child 2001; 1: 26—28.; Escobar-Morreale H., Sanchon R., San Millan J.L. et al. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 2: 527-533.; Richards G., Grumbach M., Kaplan S.L. et al. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 6: 1208—1215.; Lonning, P., Jacobs S., Jones A.L. et al. The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991; 5: 789-793.; Speiser P., Azziz R-, Baskin L.S. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 9: 4133-4160.; Hughes I., Read G. Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. Horm Res 1982; 2: 100-106.; Bachelot A., Chakhtoura Z., Samara-Boustani D. et al. Bone health should be an important concern in the care of patients affected by 21 hydroxylase deficiency. Int J Pediatr Endocrinol 2010.; RosenfieldR., BickelS., Razdan A.K. et al. Amenorrhea related to progestin excess in congenital adrenal hyperplasia. Obstet Gynecol 1980; 2: 208-215.; StikkelbroeckN., HermusA., Suliman H.M. et al. Asymptomatic testicular adrenal rest tumours in dolescent and adult males with congenital adrenal hyperplasia: basal and follow-up investigation after 2.6 years. J Pediatr Endocrinol Metab 2004; 4: 645-653.; Riad-Fahmy D., Read G., Walker R.F. et al. Steroids in saliva for assessing endocrine function. Endocr Rev 1982; 4: 367—395.; Kemp Т., Safaeian M., Miner S. et al. Oral Immunoglobulin Levels are Not a Good Surrogate for Cervical Immunoglobulin Levels. Front Oncol 2012; 2: 61.; Groschl M., Rauh M., Dorr H.G. et al. Cortisol and 17-hydroxyprogesterone kinetics in saliva after oral administration of hydrocortisone in children and young adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2002; 3: 1200-1204.; Vuorento T., Huhtaniemi I. Daily levels of salivary progesterone during menstrual cycle in adolescent girls. Fertil Steril 1992; 4: 685-690.; Gray S., Ebe L., Feldman H.A. et al. Salivary progesterone levels before menarche: a prospective study of adolescent girls. J Clin Endocrinol Metab 2010; 7: 3507-3511.; Auchus J. Management of the adult with congenital adrenal hyperplasia. Int J Pediatr Endocrinol 2010; 614107.; Klingensmith G., Garcia S., Jones H. et al. Glucocorticoid treatment of girls with congenital adrenal hyperplasia: effects on height, sexual maturation, and fertility. J Pediatr 1977; 6: 996-1004.; Richards G., Grumbach M., Kaplan S.L. et al. The effect of long acting glucocorticoids on menstrual abnormalities in patients with virilizing congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 6: 1208-1215.; Lin-Su K., Harbison M., Lekarev O. et al. Final adult height in children with congenital adrenal hyperplasia treated with growth hormone. J Clin Endocrinol Metab 2011; 6: 1710-1717.; Korth-Schutz, S., Virdis R., Saenger P. et al. Serum androgens as a continuing index of adequacy of treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1978; 3:452—458.; Kang M., Kim S., Lee Y.A. et al. Relationships of basal level of serum 17-hydroxyprogesterone with that of serum androstenedione and their stimulated responses to a low dose of ACTH in young adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Korean Med Sci2011; 11: 1454-1460.; Rosenfield R., Ehrlich E., Cleary R.F. et al. Adrenal and ovarian contributions to the elevated free plasma androgen levels in hirsute women. J Clin Endocrinol Metab 1972; 1: 92-98.; RosenfieldR., Fang V., Dupon С et al. The effects of low doses of depot estradiol and testosterone in teenagers with ovarian failure and Turner's syndrome. J Clin Endocrinol Metab 1973; 4: 574—580.; MaffeiL., Murata Y, Rochira V. etal. Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. J Clin Endocrinol Metab 2004; 1: 61—70.; Rappaport R., Cornu G., Rover P. et al. Statural growth in congenital adrenal hyperplasia treated with hydrocortisone. J Pediatr 1968; 5: 760-766.; Helleday J., Siwers В., Ritzen E.M. et al. Subnormal androgen and elevated progesterone levels in women treated for congenital virilizing 21-hydroxylase deficiency. J Clin Endocrinol Metab 1993; 4: 933—936.; Holmes-Walker D., Conway G., Honour J.W. et al. Menstrual disturbance and hypersecretion of progesterone in women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol 1995; 3: 291—296.; Abd El Dayem S., Anwar G., Salama H et al. Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia. Arch Med Sci 2010; 1: 104-110.; https://www.ped-perinatology.ru/jour/article/view/203; undefined

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/203